<DOC>
	<DOCNO>NCT01000883</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue blood patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This research study look tissue blood sample woman locally advance metastatic breast cancer</brief_summary>
	<brief_title>Correlation Molecular Markers With Response Therapy Breast Cancer Behavior</brief_title>
	<detailed_description>OBJECTIVES : - Collect , catalogue , store biological specimen patient locally advance metastatic breast cancer - To collect clinical data patient contain identifier , demographic , epidemiologic review , clinical evaluation , treatment , long-term follow-up . - To provide efficient bi-directional flow clinical information specimens laboratory clinical scientist order foster innovative translational research . OUTLINE : This multicenter study . Patients undergo core biopsy blood sample diagnosis , chemotherapy regimen , prior definitive surgery . Tumor marker assess use immunohistochemistry flow cytometry . PROJECTED ACCRUAL : A total 500 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : PATIENT ELIGIBILITY Inclusion Criteria Histologically proven metastatic breast cancer measurable evaluable disease per investigator discretion . Patients must 18 year age old . Women child bear potential must practice barrier oral contraception duration study , document surgically sterile one year postmenopausal . ECOG performance status 02 Cardiac function MUGA EF &gt; 45 % echocardiogram show normal LV function . Serum Creatinine &lt; 2.0 mg/dl . Hepatic transaminase ( alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ) ≤3.0 time upper limit normal liver metastases ≤5 time upper limit normal liver metastasis present . Bilirubin 2X normal . Seronegative HIV . Negative Hepatitis B surface antigen . Signed date informed consent . HLA A0201+ DNA genotyping . Absolute neutrophil count great 1,500/mm3 . Platelet count great 100,000/mm3 hemoglobin great equal 10 3+ expression HER2/neu original pathology ( diagnostic ) tumor sample IHC 2+ expression IHC gene amplification FISH . Patients eligible even fail treatment metastatic breast cancer trastuzumab chemotherapy agent vinorelbine progress within 12 month receive adjuvant chemotherapy use trastuzumab taxane . Exclusion Criteria Patients serious medical , cardiac , psychiatric condition , opinion investigator , would make patient unsuitable study participation would impede probable compliance protocol . Patients central nervous system metastasis must stable disease least 3 month prior study entry . Patient currently take steroid medication . Systemic steroid treatment allow . Patients fail prior therapy vinorelbine + trastuzumab eligible therapy . Patient receive hormonal cytotoxic chemotherapy within 14 day apheresis within 2830 day prior study treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>